charles_woler

Synexus announces new board

pharmafile | June 29, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Synexus, woler 

Following a management buyout Synexus has confirmed who its new board members are to steer the UK recruitment and clinical trials company forward. 

They include chairman Charles Woler (pictured), and non-executives Benjamin Harrild, Hywel Evans, Ged Gould and Simon Braham

Woler has spent the last 30 years in the healthcare industry in positions such as chairman and chief executive of Roche France, chairman of SmithKline Beecham’s European pharma business, and CEO of Cadus Pharmaceuticals.

Advertisement

Harrild is the head of UK for the Direct Lending team of BlueBay Asset Management, and was part of BlueBay’s Direct Lending business from its inception in 2011. 

Evans has wide experience in pharma and the CRO sector that includes him being managing director of Novo Nordisk UK and Takeda Pharmaceuticals. After joining Quintiles he rose to become president of Europe. 

Braham is the investment director at LDC Manchester – part of the Lloyds Group – and has over 17 years’ experience in advisory, banking, restructuring and private equity. 

Christophe Berthoux who is the chief executive of Synexus, says: “We are delighted with the strength of our new board and the expertise they bring.”

Related Content

Contract research news in brief

A round-up of recent developments in the contract research sector, including updates from Parexel, Medpace, …

Contract research news in brief

Our latest crop of contract research news includes updates from Clinipace, PPD, Cellectis bioresearch, Covance, …

Contract research news in brief

UK contract research organisation Synexus says it is reaping the benefits of its investments in …

The Gateway to Local Adoption Series

Latest content